Content
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
Article By:
ChinaBio® Today
Read
Saturday, May 28, 2022 1:00 PM EDT
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and milestone payments, plus tiered royalties.
S 3 Of 5 Cannabis Categories Gained During Fourth Week Of May
Article By:
Lorimer Wilson
Read
Saturday, May 28, 2022 9:40 AM EDT
The pure-play companies, both American and Canadian, continue to drag on the sector.
Monkeypox Outbreak Puts Focus On These Two Biotechs
Article By:
InvestorsAlley
Read
Friday, May 27, 2022 8:30 AM EDT
Just when you thought it was safe to go outside, monkeypox pops up. Still, this might not be bad news for the market, as the world will turn once again to vaccine makers to find a solution.
Pfizer To Provide Not-for-Profit Access To Medicines, Vaccines To Low Income Countries
Article By:
ESG Today
Read
Wednesday, May 25, 2022 7:20 AM EDT
Pfizer announced today the launch of ‘An Accord for a Healthier World,’ a new initiative aimed at providing all of the company’s medicines and vaccines available in the U.S. and EU on a not-for-profit basis to people in low-income countries.
In this article: PFE
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
ETF Battles: Which Pharmaceutical ETF Should You Buy? Watch PPH Vs. PJP Vs. XPH
Video By:
Ron DeLegge
Watch
Saturday, May 21, 2022 7:15 PM EDT
In this episode of ETF Battles, I referee a contest between a trio of pharmaceutical ETFs from Invesco, SPDR State Street Global Advisors, and VanEck.
Anavex: Drug Pipeline Progress
Article By:
MoneyShow.com
Read
Saturday, May 21, 2022 1:59 PM EDT
Anavex released its Q1 results and went through the list of projects in the pipeline. Not much has changed, and this lack of anything significant to get investors excited about has led to the drop off in the shares.
Week In Review: Hengrui Launches US Subsidiary To Bring Novel Medicines To Global Markets
Article By:
ChinaBio® Today
Read
Saturday, May 21, 2022 1:20 PM EDT
Hengrui Pharma launched a new company, Luzsana Biotechnology, which is devoted to making the most advanced medications available and affordable. Meanwhile, Sichuan Kelun Pharmaceutical out-licensed global rights for a molecule candidate to Merck.
This Biotech Looks Good With Increased M&A Activity
Article By:
InvestorsAlley
Read
Friday, May 20, 2022 3:49 AM EDT
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions.
S Thoughts For Thursday: Ugly And Uglier
Article By:
TalkMarkets DailyTalk
Read
Thursday, May 19, 2022 8:44 AM EDT
Saying Wednesday was not a good day for institutional and Jane and John investors alike is an understatement. At the closing bell, everything was down except for TJ Maxx.
This Dirt-Cheap Stock Looks Attractive And Pays A Market-Smashing Yield
Video By:
Jason Fieber
Watch
Monday, May 16, 2022 6:37 AM EDT
After all, if you got a health problem, you're going to do whatever is necessary to get treatment. Demand for these products is inelastic and growing. And that means a long runway for revenue, profit, and dividend growth.
In this video: GILD
Stocks Are Undervalued
Article By:
Dividend Power
Read
Sunday, May 15, 2022 7:57 AM EDT
The bear growled this past week as the S&P 500 Index skirted the (-20%) threshold. But Friday the markets bounced back, much to investors’ relief. The Index is still in a correction, although that may change next week if more bad news arrives.
S 2 Of The 5 Cannabis Categories Advance Slightly
Article By:
Lorimer Wilson
Read
Saturday, May 14, 2022 9:26 PM EDT
During the second week of May, two of the 5 categories we index showed some improvement; here, the numbers for all the stocks in all 5 categories for last week, YTD and from the 2021 peak.
Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops
Article By:
ChinaBio® Today
Read
Saturday, May 14, 2022 1:30 PM EDT
Zhaoke Ophthalmology acquired China/Southeast Asia rights for two eyedrop candidates from Visus Therapeutics in a $130 million deal. Meanwhile, Coherus Biosciences returned the US rights to market an Innovent Avastin biosimilar.